Physician profile
Simon C Jung
NPI 1992708556
$2,845.58
in general payments reported to CMS, 2019-2025
31 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $112 · 2021: $279 · 2022: $869 · 2023: $421 · 2024: $272 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $450.82 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr, Watchman Access System |
| Medtronic, INC. | $315.83 | 2021-2023 | Onyx Frontier |
| Amgen INC. | $314.06 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $252.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $221.76 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.08 | 2019-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $158.54 | 2019-2022 | |
| Pfizer INC. | $131.87 | 2019-2025 | |
| Cathworks, INC. | $96.18 | 2023 | Ffrangio |
| Astrazeneca Pharmaceuticals LP | $95.87 | 2019-2025 | Wainua |
| Edwards Lifesciences Corporation | $62.99 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $55.37 | 2019-2021 | |
| Cardiva Medical, INC. | $53.76 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $45.12 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $44.08 | 2021-2023 | Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.35 | 2019-2025 | Camzyos |
| Philips North America LLC | $27.81 | 2022 | |
| Portola Pharmaceuticals, LLC | $26.03 | 2019 | |
| Siemens Medical Solutions USA, INC. | $25.92 | 2019 | |
| Inari Medical, INC. | $25.37 | 2022 | |
| Cardiovascular Systems INC. | $22.31 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $20.36 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.96 | 2019-2022 | |
| Irhythm Technologies, INC. | $19.31 | 2023 | Zio Xt Patch |
| Chiesi USA, INC. | $15.30 | 2025 | Kengreal |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Lundbeck LLC | $13.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.32 | 2019 | |
| Gilead Sciences, INC. | $13.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.